Monoclonal Antibody Therapy 2004

[Lorraine Lescure]

> Strategies for Monoclonal Antibody Therapy 2004
> Therapeutic applications, products in clinical trials and future outlook 
> 1st & 2nd July, Hilton Kensington Hotel, London
> 
> 
> *     Monoclonal antibody therapies are becoming an important weapon in the 
> fight against cancer, autoimmune diseases, transplant rejection
> and many other diseases/conditions.
> 
> Monoclonal Antibodies Sales are forecast to grow by over 400% by 2009. 
> 
> *     This conference will address all of the relevant issues in this growing 
> sector; including methods to lower production costs and realise greater
> profits.
> 
> Themes will include:
> *     Handling cost issues of MAb treatment
> *     Overcoming problems of antibody production
> *     The future of MAb> '> s: transgenic proteins
> *     Case studies: analysis of major drugs in the market 
> *     Case studies: potential of products in clinical trials 
> *     Case studies: innovative delivery systems
> 
> Industry Leading speakers confirmed at this event:
> *     Dr. Andrea Feyereislova, Clinical Science Leader for Herceptin, Roche
> *     Bob Ward, Senior Director, Commercial Development Biologics and Small 
> Molecules, Schering-Plough
> *     Rene Imwinkelreid, Head of Lonza Biologics, Lonza Biologics
> *     Dr. Joachim Kalmus, Clinical Development Oncology, Schering
> *     Ralph Minter, Senior Research Scientist, Cambridge Antibody Technology
> *     Dr. David Humphreys, Celltech R&D, Celltech
> *     Stephen Squinto, Executive VP and Head of Research, Alexion 
> Pharmaceuticals
> *     Dr. Zhenping Zhu, Assistant Vice President Head, Antibody Technology, 
> ImClone Systems
> *     Dr. Herren Wu, Senior Director, Antibody Discovery & Protein 
> Engineering, MedImmune
> *     Dr. Lorin Roskos, Senior Director, Pharmacokinetics and Toxicology, 
> Abgenix
> 
> Who Should Attend? (job titles)
> *     Senior Director, Antibody Discovery
> *     Senior Scientist, Protein Technology Biosciences
> *     Director, Antibody Technologies / Engineering
> *     Director, Protein Engineering & Structure
> *     Senior Director, Immunology
> *     Head, Expression and Cell Science
> *     Biologics Manufacturing Development Manager
> *     Chief Technical Officer
> *     Director, Preclinical R&D
> *     Director, Product Development
> *     Vice President, Research and Development
> - plus all senior representatives involved in monoclonal antibody 
> production/research.
> 
> Places at this event are limited, please call or email me now to secure your 
> place
> 
> - PRICING -
> Attend the:
> ** Conf. + pre conf. workshop GBP 1600.00 Plus VAT 
> ** Conference only Fee: GBP1299.00 Plus VAT
> ** Pre conference workshop only Fee: GBP 650.00 Plus VAT 
> 
> - BOOKINGS -
> Booking is easy, simply contact Lorraine Lescure on:
> Telephone: +44 (0)20 8767 6711
> Fax: +44 (0)20 8767 5001
> Email: mailto:lorraine.lescure@visiongain.com
> Terms and conditions apply - see below.
> 
> I look forward to hearing from you soon.
> 
> Regards,
> Lorraine Lescure
> Account Manager 
> Visiongain b2b Conferences 
> Tel: +44 (0) 20 8767 6711 
> http://www.b2b-conferences.com
> mailto:lorraine.lescure@visiongain.com 
> 
> 
> 
> 
> Sponsorship Opportunities
> This event will provide unrivalled opportunities to promote your brand to an 
> audience of senior level delegates. 
> Options include:
> *     Full Conference Sponsorship 
> *     Exhibition Stand/Booth 
> *     Promotional Inserts 
> *     Delegate Bag Sponsor
> *     Cocktail Reception Sponsor 
> Whatever your budget, whatever your requirements we can find you a way to 
> place your brand at Monoclonal Antibody Therapy 2004.- reply to 
> lorraine.lescure@visiongain.com for more info.
> 
> 
> 
> - Agenda -
> 
> Pre-Conference Interactive Workshop
> Monoclonal Antibodies:
> Pointers for Pre-Clinical Studies
> Wednesday 30th June 2004
> Workshop Leader: Hanne Kristensen, Diatec
> 
> 09:40 Coffee and Registration
> 
> 10:00 Introduction from workshop leader
> *>  Overview of different technologies used by Diatec for
> production
> *>  Practical examples
> *>  Purification and downstream processing> 
> *>  Quality control
> *>  Benefits of using a small, ISO 9001 certified company for
> research
> *>  speed of production
> *>  flexibility
> *>  process development knowledge
> 
> About the company
> Diatec.com is a Norwegian biotechnology company producing and
> selling monoclonal antibodies for world-wide distribution. 
> 
> Strategies for Monoclonal Antibody Therapy 2004
> Day One Thursday 1st July 2004
> 
> Conference Chairman
> Bob Ward, Senior Director ,Commercial Development, Biologics and
> Small Molecules, Schering-Plough
> 
> 9:00 Registration and coffee
> 
> 9:30 Opening remarks from the Chair
> 
> INTRODUCTION
> 
> 9:40 How to Overcome Obstacles for Successful MAb Treatment
> *>  Selecting the best MAb for a given target: a rational approach to
> MAb design goals
> *>  Justifying first-in-human studies: preclinical efficacy, safety, and
> pharmacokinetics
> *>  Bad target or wrong dose? Selection of the optimum clinical dose
> *>  Managing the risk of immunogenicity
> Dr. Lorin Roskos
> Senior Director, Pharmacokinetics and Toxicology
> Abgenix
> 
> 10:20 Contract Manufacturers: A Strategic Asset for your Company
> *>  Contract manufacturers: filling the needs of biotech companies
> *>  How has this niche industry grown?
> *>  Reasons for success- full process development and regulatory
> support
> *>  Stages: vector construction, cell line development to full scale
> manufacture
> Rene Imwinkelreid
> Head of Lonza Biologics
> Lonza Biologics
> 
> 11:00 Morning Coffee
> 
> ANTIBODY PRODUCTION
> 
> 11:20 Process Development Requirements for Antibody
> Therapeutics
> *>  Approach for antibody therapeutic products
> *>  Generic process applications- cycle time reduction?
> *>  Overcoming problems posed by production capacity
> *>  Improving purification steps in the production process
> *>  Regulatory considerations
> Cristina Glad
> Executive Vice President
> BioInvent
> 
> 12:00 Strategies to Overcoming Immune Reactivity
> *>  Problems of immune response and impact on therapeutic
> antibodies
> *>  Strategies for chimeric and humanised antibodies
> *>  Molecular imprinted polymer (MIP) for engineering synthetic
> antibodies
> *>  Antibody engineering with target-activated enzymes
> Dr. Dee Athwal
> Senior Principal Scientist
> Celltech
> 
> 12:40 Lunch
> 
> 14:00 CAT-354: An IL13 Neutralising Antibody Optimised by
> Ribosome Display
> *>  Ribosome display - a versatile technology for protein engineering
> *>  Optimisation strategies - the combination of targeted and
> evolutionary approaches
> *>  The results of antibody engineering - production of antibody CAT-354
> *>  The next stages of pre-clinical development for CAT-354
> Ralph Minter
> Senior Research Scientist
> Cambridge Antibody Technology
> 
> 14:40 CASE STUDY: Simplifying the Purification of Periplasmic Fab',
> the Creation and use of New E. coli Strains
> *>  What are the benefits of Fab' production in the E. coli periplasm?
> *>  Study of host protein mutation and co-purification with Fab
> *>  The creation and use of new E. coli strains: chromosomal gene
> replacement
> *>  What are the benefits of simplified purification regimes?
> *>  The future: supplying large market indications with high quality
> drug
> Dr. David Humphreys
> Celltech R&D
> Celltech
> 
> 15:20 Afternoon Tea
> 
> THERAPEUTIC APPLICATIONS
> 
> Over two-thirds of monoclonal antibody products are for transplant rejection,
> cancer, autoimmune diseases and infectious diseases
> 
> 15:40 CASE STUDY: The Success of Remicade in treating
> Inflammatory Conditions
> *>  The role of inflammatory cytokines in patients with crohn's disease
> - the cytokine tumour necrosis factor-alpha (TNF-alpha)
> *>  How does this chimeric human: mouse antibody neutralise TNF-alpha?
> *>  Role of remicade as an anti-TNF-blocking therapy for rheumatoid
> arthritis
> *>  Clinical efficacy of infliximab
> - short and long term benefits
> - treatment of refractory Behcet syndrome
> *>  The success of remicade- marketing approvals and global sales> 
> Bob Ward
> Senior Director ,Commercial Development
> Biologics and Small Molecules
> Schering-Plough
> 
> 16:20 CASE STUDY: Zevalin, a Novel Treatment Regime
> Zevalin is the first product with a monoclonal antibody that is
> combined with a radioactive chemical for the treatment of non-Hodgkin
> lymphoma
> *>  Two part administration of Zevalin: screening and treatment
> *>  Results from safety and efficacy studies
> *>  Toxicity of treatment- limiting use
> *>  How effective is it in patients who are refractory to antibody
> treatment?
> Dr. Joachim Kalmus
> Clinical Development Oncology
> Schering
> 
> 17:00 Questions and Discussion
> 
> 17:10 Summation of day one from conference chair
> 
> 17:20 Close of Day One
> 
> Strategies for Monoclonal Antibody Therapy 2004
> Day Two Friday 2nd July 2004
> 
> 9:00 Registration and Coffee
> 
> 9:30 Opening remarks from the chair
> 
> 9:40 A Potent New Generation Anti-Tumour MUC1 Antibody
> *>  How the antibody recognises the novel tumour-specific epitope TA-MUC1
> *>  Results after 3 days of injection in the tumour of skin xenografted
> nude mice
> *>  Tumour efficacy studies in mice
> *>  Advantages over Pemtumomab: higher affinity, higher tumour
> specificity, lower binding to serum MUC1, and lower binding to
> PBMC
> *>  Primary indication: GI cancers; secondary indications: other
> carcinomas, e.g. breast, ovarian, kidney cancer
> Dr. Steffen Goletz
> Chief Scientific Office
> Leiter Forschung & Entwicklung
> NEMOD Biotherapeutics GmbH & Co.KG
> 
> 10:20 CASE STUDY: Herceptin, First FDA Approved Treatment for
> Breast Cancer
> *>  Anti-cancer benefits of Herceptin
> - binding to HER2 and blocking growth factors
> - killing of cancer cells by the stimulation of the immune system
> *>  Phase III trials: Herceptin in women with HER2 positive early stage
> breast cancer as adjuvant therapy
> *>  Results of safety and efficacy studies
> Dr. Andrea Feyereislova
> Clinical Science Leader for Herceptin
> Roche
> 
> 11:00 Morning Coffee
> 
> 11:20 CASE STUDY: Synagis, only Monoclonal Antibody Approved
> to prevent Respiratory Syncytial Virus (RSV)
> *>  First MAb successfully developed to combat infectious disease:
> mode of action
> *>  Safety and efficacy studies
> *>  Advantages over previous treatments
> *>  Development of Numax
> - second generation of Synagis
> Dr. Herren Wu
> Senior Director
> Antibody Discovery & Protein Engineering
> MedImmune
> 
> R&D: PRODUCTS IN CLINICAL TRIALS
> 
> 12:00 CASE STUDY: The Potential of Erbitux
> *>  Target: epidermal growth factor receptor
> *>  Results of clinical studies
> - biological activity in a number of tumours
> *>  Results from monotherapy
> - patients with colorectal cancer
> - metastatic colorectal cancer
> *>  Efficacy and safety of Erbitux
> - patients with advanced solid tumours
> Dr. Zhenping Zhu
> Assistant Vice President Head
> Antibody Technology
> ImClone Systems
> 
> 12:40 Lunch
> 
> 14:00 CASE STUDY: Eculizumab, Humanised MAb in a New Class of
> Drugs
> *>  Complement-5 inhibitors: activation methods
> *>  Phase I/II results for rheumatoid arthritis, nephritis, systemic lupus,
> psoriasis, dermatomyositis and pemphigoid
> *>  Predicted worldwide sales for different indications
> *>  Orphan Drug Status: treating paroxysmal nocturnal hemoglobinuria
> Stephen Squinto
> Executive VP and Head of Research
> Alexion Pharmaceuticals
> 
> FUTURE OUTLOOK: TRANSGENIC PROTEINS
> 
> 14:40 Transgenic Plants: A New Model to meet Production Needs
> *>  Potential of this segment
> - is it really a viable alternative?
> *>  Large scale genetically engineered proteins an option for less
> complex proteins?
> *>  Overcoming technical issues
> *>  Challenges
> Dominique Mison
> Bio-industrial Director
> Meristem Therapeutics
> 
> 15:20 Afternoon Tea
> 
> INNOVATIVE DELIVERY SYSTEMS
> 
> 15:40 CASE STUDY: Crystalline MAb Formulations for
> Subcutaneous Delivery
> *>  MAb's: limitations of current administration and use> 
> *>  Altus Crystalomics TM protein crystallisation technology for
> subcutaneous delivery
> *>  Pharmacokinetic profile and pharmacodynamic efficacy in vivo
> *>  Advantages of delivery method: higher concentrations, low dose
> volume, low viscosity, high stability
> *>  New opportunities for biopharmaceutical applications
> Dr. Sujit Basu
> Group Leader
> Parenteral Formulation and Delivery
> Altus Biologics
> 
> 16:20 Questions and Discussion
> 
> 16:40 Chairman Summation
> 
> 16:50 Close of Conference
> 
> 
> 
> 
> Visiongain/B2B Conferences produce a range of timely business information 
> material, if you wish to receive information of new products, simply reply to 
> this email with ' New Products info' in the subject box
> 
> 
> 
> 
> 
> 
> 
> 
> 
> 
> Terms & Conditions
> NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for 
> an invoice to be raised will be treated as an official booking and will be 
> subject to the cancellation policy as outlined below.
> Cancellations/substitutions and name changes: All bookings carry a 50% 
> liability after the booking has been made, by post fax, email or web. There 
> will be no refunds for cancellations received on or after one month before 
> the start of the conference (e.g. cancellation on or after 20th January for a 
> conference starting on 20th February). If you decide to cancel after this 
> date the full invoice remains payable. Conference notes, which are available 
> on the day, will be sent to you. Unfortunately we are not able to transfer 
> places between conferences and executive briefings. However if you are unable 
> to attend the event you may make a substitution/name change at any time as 
> long as we are informed in writing by e-mail, fax or post. Name changes and 
> substitutions must be from the same company and are not transferable between 
> companies or countries.
> 
> Indemnity: visiongain Ltd reserve the right to change the 
> conference/executive briefing content, timing, speakers or venue without 
> notice. The event may be postponed or cancelled due to acts of terrorism, 
> war, extreme weather conditions, industrial action, acts of God or any event 
> beyond the control of visiongain Ltd. If such a situation arises we will 
> endeavour to reschedule the event. However, visiongain Ltd cannot be held 
> responsible for any cost, damage or expenses, which may be incurred by the 
> customer as a consequence of the event being postponed or cancelled. We 
> therefore strongly advise all customers to take out insurance to cover the 
> cost of the registration, travel and expenses.
> To unsubscribe please reply with unsubscribe in the subject line. 
> Data protection: Visiongain Ltd gathers and manages data in accordance with 
> the Data Protection Act 1998. Information contained about you may be used to 
> update you on visiongain Ltd products and services via post, telephone, fax 
> or email, unless you state otherwise. If you wish your details to be amended, 
> please send your request to the Database Manager, visiongain Ltd, 40 Tooting 
> High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in 
> the subject line. Please allow approximately 7 days for your removal or 
> update request, you may receive additional pieces of communication from 
> visiongain Ltd during the transitional period, whilst the changes come into 
> effect.
> 
> 
> 
> 
> 
> 
> 
> 
> 
> 
> 
> 
> 
> 
#####################################################################################

This email has been scanned by MailMarshal, an email content filter. 

#####################################################################################